# Imaging of Patients With Known or Suspected Somatostatin Receptor Positive Neuroendocrine Tumors Using Cu64-DOTATATE

Source: https://onco.cc/trials/nct03673943/  
OnCo record `nct03673943` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Somatostatin receptor PET in Neuroendocrine tumours, run by Radiomedix, Inc., completed.

## Summary

Imaging of Patients With Known or Suspected Somatostatin Receptor Positive Neuroendocrine Tumors Using Cu64-DOTATATE is a phase 3 interventional study registered as NCT03673943 by Radiomedix, Inc., with 63 participants recorded, started 2018-08-23 and reaching its primary completion in 2019-03-23. Interventions recorded: 64Cu-DOTATATE. Conditions recorded: Neuroendocrine Tumors.

Linked to the technology Somatostatin receptor PET because the registry names it ("64cu dotatate") among its interventions and Neuroendocrine tumours among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT03673943
- Phase: 3
- Setting: An Open-label, Single-dose, Single Arm, Single-center Clinical Trial of 64Cu(Copper)-DOTATATE (NETMedix™) PET-CT Scan for Imaging Patients With Known or Suspected Somatostatin Receptor-positive Neuroendocrine Tumors (NETs)
- Sponsor: Radiomedix, Inc.
- Enrolled: 63

## Sources

- ClinicalTrials.gov NCT03673943: https://clinicaltrials.gov/study/NCT03673943

## Connected records

- cancers: [Neuroendocrine tumours](https://onco.cc/cancers/neuroendocrine/)
- technologies: [Somatostatin receptor PET (68Ga/64Cu-DOTATATE)](https://onco.cc/technologies/sstr-pet/)
- companies: [RadioMedix](https://onco.cc/companies/radiomedix/)

---
JSON: https://onco.cc/api/v1/entities/nct03673943.json